Evaxion biotech wins frost & sullivan 2021 enabling technology leadership award

Copenhagen, denmark, oct. 14, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has been awarded this year's enabling technology leadership award in the artificial intelligence-enabled drug discovery industry by global research and consulting firm frost & sullivan. the award recognizes evaxion's pioneering spirit towards cutting-edge technology and data-driven decision-making.
EVAX Ratings Summary
EVAX Quant Ranking